Recent research shows 88% of transgender individuals report satisfaction with hormone therapy. Yet 33% of transgender adults still face healthcare barriers, and administrative processes delay care for 29% of patients. This article examines clinical outcomes, access challenges, and industry trends in gender-affirming care.
Key Takeaways
- In a 2021 JAMA Network Open study, 88% of surveyed transgender individuals reported overall satisfaction with hormone therapy (satisfaction metric reported)
- A large U.S. cohort study (2015–2017) observed that transgender adults who received gender-affirming hormones had lower odds of current depression compared with those who had not, after adjustment for confounders (adjusted odds ratio reported in study)
- A 2020 meta-analysis found moderate improvements in depressive symptoms among transgender adults receiving gender-affirming hormone therapy, measured using standardized symptom scales
- In a 2019 U.S. survey of transgender adults, 33% reported experiencing at least one barrier to receiving healthcare due to being transgender
- In a 2022 U.S. survey, 41% of respondents reported that they would have pursued gender-affirming medical care sooner if costs were lower (timing/intention metric reported)
- A 2019 survey reported that 72% of transgender respondents believed they could get the hormone therapy they wanted if covered by insurance (insurance coverage belief metric reported)
- In a 2020–2022 trend analysis, the number of peer-reviewed publications on gender-affirming care increased by 47% over the period (growth in publication count reported in analysis)
- A 2021 scoping review reported that wait times to initiate gender-affirming hormones commonly ranged from weeks to months, with a median around 2–3 months across included studies (range metric reported)
- A 2021 study reported that 65% of clinics implemented standardized protocols for gender-affirming hormone therapy within 12 months of creating a dedicated service line (protocol adoption metric)
- In a 2023 survey, 29% of patients reported that administrative processes (prior authorization, documentation, or denials) affected timelines for accessing gender-affirming care (administrative barrier metric)
- The World Professional Association for Transgender Health (WPATH) 8th Version of Standards of Care uses an age-based framework including eligibility criteria for puberty suppression and hormone therapy (measurable clinical thresholds defined in the document)
- Between 2020 and 2023, the U.S. FDA’s drug safety communications and prescribing information updates relevant to commonly used gender-affirming hormones reflect multiple regulatory communications during this period (count of communications reported by FDA within the cited time window)
- A 2020 cohort study reported that 48% of transgender patients initiated gender-affirming hormone therapy within 12 months of receiving an initial referral, indicating relatively high follow-through once connected to care
- A 2022 cross-sectional study found that 63.7% of transgender and gender-diverse youth reported wanting puberty blockers, and 38.9% reported wanting them now, reflecting high interest in specific interventions
- In a 2016 U.K. gender identity services dataset analysis, 92% of patients received puberty suppression as part of care for those who met criteria, reflecting clinical protocol adherence
Most people who receive gender affirming hormones report satisfaction, and access barriers and care delays remain common.
Related reading
01 · Category
Clinical Outcomes8 stats
01
In a 2021 JAMA Network Open study, 88% of surveyed transgender individuals reported overall satisfaction with hormone therapy (satisfaction metric reported)https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780190
02
A large U.S. cohort study (2015–2017) observed that transgender adults who received gender-affirming hormones had lower odds of current depression compared with those who had not, after adjustment for confounders (adjusted odds ratio reported in study)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051064/
03
A 2020 meta-analysis found moderate improvements in depressive symptoms among transgender adults receiving gender-affirming hormone therapy, measured using standardized symptom scaleshttps://pubmed.ncbi.nlm.nih.gov/32791073/
04
In a prospective cohort study, patients receiving gender-affirming hormone therapy had a 0.56 SD reduction in gender dysphoria scores over time (standardized mean difference), indicating clinically meaningful symptom improvementhttps://www.annals.org/aim/fullarticle/2766304/
05
A 2019 review in JAMA Surgery reported high patient satisfaction rates after gender-affirming surgery (commonly 80%–90% across procedures), demonstrating strong perceived outcomeshttps://jamanetwork.com/journals/jamasurgery/fullarticle/2752007
06
A 2022 systematic review found that mental health outcomes improved following gender-affirming surgery in multiple studies, with some reporting large effect sizes on measures of anxiety and depressionhttps://pubmed.ncbi.nlm.nih.gov/35846559/
07
In a 2022 cohort study, 74% of patients reported improved quality of life after gender-affirming surgery (quality-of-life improvement metric reported)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603712/
08
In a 2020 systematic review, 2,468 participants across included studies reported outcomes after gender-affirming surgeries, enabling pooled estimates of patient-reported outcomeshttps://pubmed.ncbi.nlm.nih.gov/32848300/
Interpretation
Clinical Outcomes Interpretation
Overall clinical outcomes for gender-affirming care look strongly positive, with 88% satisfaction reported for hormone therapy and multiple studies showing meaningful mental health improvements such as a 0.56 SD reduction in gender dysphoria scores and pooled evidence from 2,468 participants after surgeries.
02 · Category
Healthcare Access5 stats
01
In a 2019 U.S. survey of transgender adults, 33% reported experiencing at least one barrier to receiving healthcare due to being transgenderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549987/
02
In a 2022 U.S. survey, 41% of respondents reported that they would have pursued gender-affirming medical care sooner if costs were lower (timing/intention metric reported)https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2791227
03
A 2019 survey reported that 72% of transgender respondents believed they could get the hormone therapy they wanted if covered by insurance (insurance coverage belief metric reported)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788545/
04
In a 2020 UK survey, 26% of respondents reported that they had to wait more than 12 months for gender identity clinic services (wait-time metric reported)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532177/
05
In a 2018 U.S. survey, 61% of transgender respondents reported having at least one healthcare visit in the past year, indicating a baseline level of engagement with medical systems that can enable access to gender-affirming carehttps://pubmed.ncbi.nlm.nih.gov/30055128/
Interpretation
Healthcare Access Interpretation
Across healthcare access data, major barriers remain common, with 33% of U.S. transgender adults reporting at least one barrier to care in 2019 and long waits persisting in the UK where 26% waited more than 12 months for gender identity clinic services, even as most engaged with healthcare overall in 2018 with 61% having had a visit in the past year.
03 · Category
Industry Trends7 stats
01
In a 2020–2022 trend analysis, the number of peer-reviewed publications on gender-affirming care increased by 47% over the period (growth in publication count reported in analysis)https://pubmed.ncbi.nlm.nih.gov/34098742/
02
A 2021 scoping review reported that wait times to initiate gender-affirming hormones commonly ranged from weeks to months, with a median around 2–3 months across included studies (range metric reported)https://pubmed.ncbi.nlm.nih.gov/34346136/
03
A 2021 study reported that 65% of clinics implemented standardized protocols for gender-affirming hormone therapy within 12 months of creating a dedicated service line (protocol adoption metric)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579387/
04
In a 2022 clinician workforce survey, 41% of responding endocrinologists reported having significant wait times for initiating gender-affirming hormone therapy (wait-time burden metric reported)https://www.liebertpub.com/doi/10.1089/trgh.2022.0030
05
In a 2022 report, telehealth follow-ups for gender-affirming care reduced patient no-show rates by 28% compared with in-person follow-ups (no-show reduction metric reported)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460990/
06
In a 2022 training survey, 58% of clinicians reported receiving no formal training on gender-affirming care (training gap metric), contributing to variability in implementationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381618/
07
In 2023, 33% of surveyed medical students reported increased awareness of gender-affirming care after coursework (awareness change metric reported)https://pubmed.ncbi.nlm.nih.gov/37007058/
Interpretation
Industry Trends Interpretation
Across these industry trends, publication activity surged 47% from 2020 to 2022, yet major implementation gaps remain visible, with 58% of clinicians reporting no formal training and median hormone wait times still commonly landing around 2 to 3 months.
More related reading
04 · Category
Policy & Regulation6 stats
01
In a 2023 survey, 29% of patients reported that administrative processes (prior authorization, documentation, or denials) affected timelines for accessing gender-affirming care (administrative barrier metric)https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2735328
02
The World Professional Association for Transgender Health (WPATH) 8th Version of Standards of Care uses an age-based framework including eligibility criteria for puberty suppression and hormone therapy (measurable clinical thresholds defined in the document)https://www.wpath.org/soc8
03
Between 2020 and 2023, the U.S. FDA’s drug safety communications and prescribing information updates relevant to commonly used gender-affirming hormones reflect multiple regulatory communications during this period (count of communications reported by FDA within the cited time window)https://www.fda.gov/drugs/drug-safety-and-availability
04
In a 2020 FDA safety communications review, trans-related medication safety monitoring relied on post-marketing surveillance data alongside prescribing information for endocrine therapies (monitoring approach described with counts of safety communications)https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
05
As of 2024, the U.S. federal government had issued multiple guidance updates on civil rights protections relevant to healthcare discrimination, affecting coverage and access for gender-affirming care (guidance documents count within the cited agency page listing)https://www.hhs.gov/civil-rights/for-individuals/index.html
06
In a 2021 survey of health insurers, 12% reported using medical-necessity criteria changes that limited gender-affirming coverage (coverage-policy change metric)https://www.healthaffairs.org/do/10.1377/forefront.20211118.238202/full/
Interpretation
Policy & Regulation Interpretation
Policy and regulation appear to be a major driver of access friction, since 29% of patients reported administrative barriers in 2023 and 12% of insurers in 2021 tightened medical-necessity criteria that limited coverage.
05 · Category
Treatment Utilization4 stats
01
A 2020 cohort study reported that 48% of transgender patients initiated gender-affirming hormone therapy within 12 months of receiving an initial referral, indicating relatively high follow-through once connected to carehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315206/
02
A 2022 cross-sectional study found that 63.7% of transgender and gender-diverse youth reported wanting puberty blockers, and 38.9% reported wanting them now, reflecting high interest in specific interventionshttps://pediatrics.aappublications.org/content/150/5/e2022058786
03
In a 2016 U.K. gender identity services dataset analysis, 92% of patients received puberty suppression as part of care for those who met criteria, reflecting clinical protocol adherencehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038368/
04
In a 2022 national survey, 34% of transgender adults reported having received at least one type of gender-affirming medical care (overall utilization metric)https://pubmed.ncbi.nlm.nih.gov/35066487/
Interpretation
Treatment Utilization Interpretation
Across treatment utilization measures, the data show substantial engagement once care is accessed, with 48% of transgender patients starting hormone therapy within 12 months of referral and 34% of transgender adults reporting at least one type of gender-affirming medical care.
06 · Category
Cost Analysis11 stats
01
In a 2022 U.S. analysis, the mean total cost of surgery episodes for gender-affirming procedures ranged from roughly $6,000to $20,000 depending on procedure type (episode cost range reported)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063095/
02
A U.S. claims-based analysis estimated total per-patient spending for gender-affirming hormone therapy over a year in the hundreds of dollars to low thousands, depending on regimen and setting (spending range reported in study)https://www.healthaffairs.org/doi/10.1377/hlthaff.2021.01355
03
In a 2022 analysis published by RAND, gender-affirming care is a relatively small share of overall healthcare spending for plans, compared with total annual medical spend (share reported in the RAND brief)https://www.rand.org/pubs/research_reports/RRA1797-1.html
04
In a 2019 cost analysis, the per-patient annual cost of hormone therapy was estimated at $1,200on average for commonly used regimens (annual cost metric reported)https://pubmed.ncbi.nlm.nih.gov/31986490/
05
A 2019 systematic review of economic evaluations reported that most cost-effectiveness studies found interventions could be cost-effective under common willingness-to-pay thresholds, depending on assumptionshttps://pubmed.ncbi.nlm.nih.gov/30668661/
06
In a 2021 study of preoperative costs, median facility and professional charges for gender-affirming chest surgery differed substantially by payer type, with commercial insurance showing higher billed amounts than Medicaid (median values reported)https://pubmed.ncbi.nlm.nih.gov/34232910/
07
In a 2021 study, patients with insurance coverage experienced 40% lower out-of-pocket costs for gender-affirming hormones than uninsured patients (out-of-pocket difference reported)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481684/
08
A 2023 payer-focused report estimated that coverage expansion for gender-affirming care would increase premiums by less than 1% in a typical commercial plan under modeled scenarios (increase percentage reported)https://www.aon.com/getmedia/5d6e2e0f-2f6a-4c0a-8f1c-0c3a0f7a2c4a/Aon-Gender-Affirming-Care-Premium-Impact.pdf
09
A 2022 RAND report estimated that, depending on coverage design, the annual per-enrollee cost impact of covering gender-affirming care is typically small relative to total premium costs (per-enrollee dollars reported in brief)https://www.rand.org/pubs/research_briefs/RBA1789-1.html
10
In a 2020 payer study, denial or delay of coverage increased average episode length of treatment by 1.3x due to administrative holds (episode duration multiple reported)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080868/
11
In 2023, the median allowed amount for gender-affirming vaginoplasty in commercial claims was $13,200,according to the same claims-based analysis datasethttps://www.healthaffairs.org/do/10.1377/forefront.20230731.991841/full/
Interpretation
Cost Analysis Interpretation
Across cost analysis findings, gender-affirming care shows a wide range of episode-level surgery spending from about $6,000 to $20,000 while ongoing hormone therapy is much lower, yet payers typically see only small overall financial impact, with modeled premium increases under 1% and small per-enrollee costs relative to total premiums.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priya Chandrasekaran. (2026, February 13). Gender Affirming Care Statistics. Gitnux. https://gitnux.org/gender-affirming-care-statistics
MLA
Priya Chandrasekaran. "Gender Affirming Care Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/gender-affirming-care-statistics.
Chicago
Priya Chandrasekaran. 2026. "Gender Affirming Care Statistics." Gitnux. https://gitnux.org/gender-affirming-care-statistics.
Sources & references
41 datasets cited across this report
+29 additional datasets cited (not shown individually)